NervGen Pharma Corp.
NGEN.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.05M | 1.61M | 1.48M | 1.62M | 1.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.25M | 4.39M | 3.69M | 3.58M | 2.55M |
| Operating Income | -5.25M | -4.39M | -3.69M | -3.58M | -2.55M |
| Income Before Tax | -3.83M | -5.72M | -1.74M | -6.33M | -3.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.83M | -5.72M | -1.74M | -6.33M | -3.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.83M | -5.72M | -1.74M | -6.33M | -3.21M |
| EBIT | -5.25M | -4.39M | -3.69M | -3.58M | -2.55M |
| EBITDA | -5.24M | -4.37M | -3.67M | -3.57M | -2.52M |
| EPS Basic | -0.05 | -0.08 | -0.03 | -0.11 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.05 | -0.02 | -0.07 | -0.03 |
| EPS Diluted | -0.05 | -0.08 | -0.03 | -0.11 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.05 | -0.02 | -0.07 | -0.03 |
| Average Basic Shares Outstanding | 70.07M | 69.95M | 60.21M | 59.56M | 59.42M |
| Average Diluted Shares Outstanding | 70.07M | 69.95M | 60.21M | 59.56M | 59.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
